The effect of Enzalutamide and Radium-233 chloride for castration-resistant prostate cancer patients with bone metastasis

Trial Profile

The effect of Enzalutamide and Radium-233 chloride for castration-resistant prostate cancer patients with bone metastasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2018 Status changed from recruiting to discontinued.
    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top